All Oncology News

The addition of a focal boost to the intraprostatic lesion was found to improve biochemical disease-free survival in patients undergoing treatment with external beam radiotherapy for localized intermediate- and high-risk prostate cancer.

Patients with mismatch repair–deficient recurrent or advanced endometrial cancer gained an efficacious and safe treatment option with the addition of dostarlimab-gxly.

The combination of bempegaldesleukin plus nivolumab continued to produce promising antitumor activity with favorable tolerability when used in the frontline treatment of patients with metastatic melanoma, according to findings from a phase 2 cohort of the phase 1/2 PIVOT-2 trial.

Zev A. Wainberg, MD, and Jaffer A. Ajani, MD, discuss how to best utilize information provided to inform treatment decisions, treatment approaches for patients with newly diagnosed RAS wild-type mCRC, and factors that affect influence selecting a 2- vs 3-drug chemotherapy regimen.

Within the hierarchy of clinical trials, phase 3 randomized studies remain the gold standard, though some argue that appropriately designed meta-analysis of multiple studies provides even more definitive and meaningful insight.

Marwan Fakih, MD, discusses the efficacy of regorafenib plus nivolumab in patients with pMMR/MSS CRC, the potential for VEGFR/PD-1 inhibitor combination regimens in this population, and future directions for research.

Despite the failure of several strategies to improve the outcomes of patients with newly diagnosed diffuse large B-cell lymphoma, there appears to be substantial and growing progress in the treatment of relapsed disease.

Prithviraj Bose, MD, discusses data with pelabresib from the MANIFEST trial and future research directions for BET inhibition in patients with myelofibrosis.

The combination of eprenetapopt and azacitidine demonstrated a promising safety profile as well as encouraging clinical activity in a high-risk population of patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.

Richard Gorlick, MD, expands on the process of identifying these novel targets in osteosarcoma and the clinical implications of this research for these patients.

The FDA has granted a fast track designation to berubicin as a potential therapeutic option for patients with recurrent glioblastoma multiforme.

Sarabdeep “Sabi” Singh has been named executive vice president and chief operating officer of Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.

The BNT162b2 mRNA COVID-19 vaccine may demonstrate decreased efficacy in patients with certain types of hematologic cancers, such as chronic lymphocytic leukemia and multiple myeloma.

Fixed-duration ibrutinib plus venetoclax produced superior progression-free survival when compared with chlorambucil plus obinutuzumab in the frontline treatment of patients with chronic lymphocytic leukemia, with durable responses observed in those who achieved undetectable minimal residual disease negativity.

Naveen Pemmaraju, MD, discusses approaches to adequately manage symptoms experienced by patients with myelofibrosis, challenges faced with defining disease progression, and strategies for when to initiate or delay treatment.

The median progression-free survival benefit experienced by patients with metastatic breast cancer who were HER2 positive at initial diagnosis and who were receiving standard HER2-directed therapies proved to be more favorable than what was reported in those who were HER2 negative and switched to HER2 positive status.

Treatment with darolutamide induced a low cumulative incidence of hormone treatment–related adverse effects that was comparable to treatment with placebo in patients with nonmetastatic castration-resistant prostate cancer, according to findings from a safety analysis of the phase 3 ARAMIS trial.

Abiraterone acetate plus prednisone should be considered as the first treatment choice for patients with newly diagnosed metastatic castration-resistant prostate cancer if fatigue is a concern.

Eighty-five percent of patients with nonmetastatic castration-resistant prostate cancer who crossed over from placebo to darolutamide in the phase 3 ARAMIS trial experienced a maximum prostate-specific antigen decline of at least 50% at any time of crossover.

Tucatinib and ONT-993 were found to be detectable in the cerebrospinal fluid of all patients with leptomeningeal metastases from HER2-positive metastatic breast cancer who received treatment with tucatinib plus trastuzumab and capecitabine.

Investigators demonstrated that the benefit of androgen deprivation therapy was extended with the addition of apalutamide for patients with metastatic castration-sensitive prostate cancer regardless of disease volume.

Intense androgen receptor inhibition with neoadjuvant apalutamide did not complicate robotic prostatectomy surgical outcomes.

Halle Moore, MD, discusses the data that support the use of CDK4/6 inhibitors plus endocrine therapy in HR-positive, HER2-negative breast cancer, how to select between available CDK4/6 inhibitors in the metastatic setting, and the current state of this treatment approach for patients with early-stage disease.

The FDA has approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro) plus pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide and a proteasome inhibitor

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer.

Patients with a urological cancer who were also infected with COVID-19 and undergoing elective surgery for their disease, were found to have a significantly higher likelihood of experiencing respiratory complications and mortality than those without the virus.

Sequential combination treatment with mytomicin chemotherapy and Bacillus Calmette-Guérin (BCG) showed comparable safety compared with BCG alone in patients with high-risk non-muscle–invasive bladder cancer.

The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic.

Molecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.

The FDA has granted a regular approval to enfortumab vedotin-ejfv and has expanded the agent's indication to include adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and who have received 1 or more prior lines of therapy.